[Year:2021] [Month:July-August] [Volume:13] [Number:4] [Pages:6] [Pages No:245 - 250]
Aim and objective: To identify characteristics of coronavirus disease-2019 (COVID-19) infection in pregnancy, maternal, and fetal outcomes and study changes in inflammatory markers and chest imaging findings.
Materials and methods: This study is an observational study on pregnant COVID positive women admitted for treatment in the Maharaja Tukojirao Holkar Dedicated COVID Hospital, Indore, Madhya Pradesh, India from April 17, 2020, to April 30, 2021. There were two notable peaks of infection with different clinical characteristics. Group A included data from April 17, 2020, to February 28, 2021, and group B from March 1, 2021, to April 30, 2021. A detailed comparative analysis was done, comparing clinical parameters, investigational findings, and outcomes in both groups.
Results: The incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnant women based on admissions in our hospital was 1.26/1,000 maternities. Group A had 94 cases, while group B that included the second wave of infection had 103 cases. The demographic profile of women was comparable in both groups. About 84.04% of women in group A were asymptomatic. In group B, 27.18% were asymptomatic. Laboratory parameters were deranged more so in group B. In group A, 41.49% of women reported in labor and there were no mortalities. In group B, 25.24% reported in labor, those <31 weeks were 60.64%, and there were 12 mortalities. Cesarean section was done in 56.52% of group A, 39.06% of group B, and there were 12.5% of abortions. All of the babies who delivered by vaginal route or cesarean section tested negative within 12 hours of delivery irrespective of maturity.
Conclusion: In our study, we noticed two notable peaks of SARS-CoV-2 infection, first onset was from April 2020 which gradually declined till February 2021 but majority of pregnant women remained asymptomatic, those at term delivered, others recovered within 8 to 14 days, and majority did not require any advanced treatment or oxygen support. Starting from April 2021, there was a resurgence of cases with moderate-to-severe disease, morbidities, and even deaths. All novel management options were given on individualized basis including remdesivir, IVIG, and bevacizumab, which proved to be lifesaving in some. All babies delivered tested were SARS-CoV-2 negative and there was a good neonatal outcome.